Drugs / Xingnaojing
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 44 trials | ||||||
| Phase 4 | NCT04150835 | Mar 2020 → Dec 2021 | ischemic stroke | Dongzhimen Hospital, Beijing | Unknown | No outcome recorded |
| Phase 4 | NCT04946474 | Jun 2019 → Jul 2020 | intracerebral hemorrhage | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02728180 | Mar 2016 → Dec 2019 | ischemic stroke | Dongzhimen Hospital, Beijing | Unknown | No outcome recorded |
| Phase 4 | NCT00796380 | Dec 2008 → Nov 2009 | epilepsy | Shenzhen Children's Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04813445 | May 2021 → Jun 2022 | ischemic stroke | Dongzhimen Hospital, Beijing | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xingnaojing | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04813445 ↗ |
| Known as | Xingnaojing injection | “Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.” NCT04150835 ↗ |
| Route | Intravenous | “intravenously administered Xingnaojing injection” NCT02728180 ↗ |